Lyra Therapeutics, Inc. LYRA
Set alert
At close · Oct 29
After hours · Oct 29, 4:00 PM ET
- YTD
- -93.83%
- 1 year
- -96.74%
- Open
- 0.4501
- Prev close
- 0.19
- Mkt cap
- 337.23K
- Vol
- 5.47K
- Avg vol
- 907
- EPS
- -18.62
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.3623
- High
- 0.52
- Forward P/E
- -0.24
- Beta
- -0.04
- Short ratio
- 0.89
- Inst. own
- 59.75%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2024
- 50-d avg
- 0.2216
- 200-d avg
- 1.32
- 1y target
- 1.25
Key statistics
- Market cap
- 11.45M
- Enterprise value
- -4.52M
- Trailing P/E
- 0.00
- Forward P/E
- -0.24
- PEG ratio
- 0.00
- Price / sales
- 7.78
- Price / book
- 0.56
- EPS (TTM)
- -1.49
- Beta
- -0.04
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 1.47M
- Revenue growth
- -64.20%
- Free cash flow
- -45.86M
- Total cash
- 51.63M
- Total debt
- 35.32M
- Return on equity
- -186.18%
- Shares outstanding
- 65.46M
- Short % of float
- 4.20%
- 50-day average
- 0.2216
- 200-day average
- 1.32
Analyst view
Consensus: none
- Target (low)
- 0.50
- Target (mean)
- 1.25
- Target (high)
- 2.00
- Strong buy0
- Buy1
- Hold4
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate -0.13.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.23 | -0.18 | +0.05 | +21.74% |
| Aug 14, 2024 | Jun 1, 2024 | -0.34 | -0.29 | +0.05 | +14.71% |
| Aug 14, 2024 | Jun 1, 2024 | -0.34 | — | — | — |
| Apr 30, 2024 | Mar 1, 2024 | -0.26 | — | — | — |
| Apr 30, 2024 | Mar 1, 2024 | -0.26 | -0.35 | -0.09 | -34.62% |
| Mar 21, 2024 | Dec 1, 2023 | -0.33 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 15, 2024 | Cantor Fitzgerald | reit | — | Overweight |
| Aug 15, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Jun 20, 2024 | Cantor Fitzgerald | reit | — | Overweight |
| May 7, 2024 | HC Wainwright & Co. | down | Buy | Neutral |
| May 7, 2024 | Jefferies | down | Buy | Hold |
| May 6, 2024 | BTIG | down | Buy | Neutral |
About Lyra Therapeutics, Inc.
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- lyratherapeutics.com
News
- Lyra Therapeutics (OTCMKTS:LYRA) versus Hypermarcas (OTCMKTS:HYPMY) Head-To-Head Analysis
- ARS Pharmaceuticals (NASDAQ:SPRY) vs. Lyra Therapeutics (OTCMKTS:LYRA) Head to Head Review
- Head to Head Contrast: Lyra Therapeutics (OTCMKTS:LYRA) versus Cronos Group (NASDAQ:CRON)
- Financial Comparison: Crinetics Pharmaceuticals (NASDAQ:CRNX) and Lyra Therapeutics (OTCMKTS:LYRA)
- Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- Gold Rises Sharply; Lyra Therapeutics Shares Plunge
- 12 Health Care Stocks Moving In Monday's Intraday Session
- US Stocks Lower; Dow Tumbles Over 250 Points
Your note
Sign in to keep a note on LYRA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDERSON EDWARD T | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | May 30, 2023 | 0 |
| CAVALIER JASON | Chief Financial Officer | Stock Award(Grant) | Oct 15, 2024 | 100,000 |
| NBVM GP, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | May 30, 2023 | 0 |
| NOYES CORINNE | Officer | Stock Award(Grant) | Jan 30, 2023 | 36,667 |
| PALASIS MARIA | Chief Executive Officer | Stock Award(Grant) | Oct 15, 2024 | 300,000 |
| PERCEPTIVE ADVISORS LLC | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | May 30, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Perceptive Advisors Llc | 19.49% | 12,757,562 | 2.23M | Sep 29, 2024 |
| Citadel Advisors Llc | 7.29% | 4,772,816 | 834.76K | Sep 29, 2024 |
| Blackrock Inc. | 4.57% | 2,993,626 | 523.59K | Sep 29, 2024 |
| Samsara BioCapital, LLC | 4.25% | 2,780,261 | 486.27K | Sep 29, 2024 |
| Vanguard Group Inc | 2.72% | 1,779,263 | 311.19K | Sep 29, 2024 |
| Ikarian Capital, LLC | 1.61% | 1,056,829 | 184.84K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Russell 2000 ETF | 3.55% | 2,323,232 | 406.33K | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 1.52% | 992,543 | 173.59K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.70% | 455,832 | 79.72K | Sep 29, 2024 |
| iShares Russell 2000 Growth ETF | 0.63% | 409,835 | 71.68K | Oct 30, 2024 |
| Fidelity Small Cap Index Fund | 0.49% | 323,038 | 56.50K | Aug 30, 2024 |
| Fidelity Extended Market Index Fund | 0.36% | 232,767 | 40.71K | Oct 30, 2024 |